LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Xencor Inc

Xencor Inc

Aperta

SettoreSettore sanitario

11.27 -0.27

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.09

Massimo

11.59

Metriche Chiave
By Trading Economics
Entrata	-214M -129M
Vendite	-24M 4.5M
EPS	-1.71
Margine di Profitto	-2,854.65
Dipendenti	260
EBITDA	-81M -75M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+129.68% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-170M 820M
Apertura precedente	11.54
Chiusura precedente	11.27

Notizie sul Sentiment di mercato

By Acuity

34%

66%

81 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

7.87 / 10.84 Supporto e resistenza

Xencor Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 mag 2026, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mag 2026, 16:49 UTC

Utili

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mag 2026, 16:26 UTC

I principali Market Mover

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mag 2026, 23:51 UTC

Discorsi di Mercato

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mag 2026, 23:30 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

21 mag 2026, 23:30 UTC

Discorsi di Mercato

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mag 2026, 22:33 UTC

Acquisizioni, Fusioni, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mag 2026, 21:53 UTC

Utili

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mag 2026, 21:02 UTC

Utili

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mag 2026, 20:55 UTC

Utili

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mag 2026, 20:30 UTC

Azioni calde

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mag 2026, 20:20 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

21 mag 2026, 20:20 UTC

Discorsi di Mercato

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mag 2026, 20:20 UTC

Utili

Webull 1Q Adj EPS 3c >BULL

21 mag 2026, 20:20 UTC

Utili

Webull 1Q Rev $159.9M >BULL

21 mag 2026, 20:18 UTC

Discorsi di Mercato

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mag 2026, 20:18 UTC

Utili

Webull 1Q Loss/Shr 4c

21 mag 2026, 19:43 UTC

Discorsi di Mercato

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mag 2026, 18:58 UTC

Utili

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mag 2026, 18:15 UTC

Discorsi di Mercato

Gold Higher For Second Consecutive Day -- Market Talk

21 mag 2026, 17:40 UTC

Discorsi di Mercato

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mag 2026, 17:04 UTC

Discorsi di Mercato

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mag 2026, 17:01 UTC

Utili

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mag 2026, 16:20 UTC

Discorsi di Mercato

Utili

Stellantis Targets Distant but Constructive -- Market Talk

21 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Xencor Inc Previsione

Obiettivo di Prezzo

By TipRanks

129.68% in crescita

Previsioni per 12 mesi

Media 26 USD 129.68%

Alto 43 USD

Basso 13 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Xencor Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Xencor Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

7.87 / 10.84Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

81 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.